About US
Contact us
-
Are post-merger AbbVie shares 'unsustainably cheap'? One analyst thinks soWith its megamerger with Allergan finally in the books, AbbVie is officially a colossus with a bustling drug portfolio and a few strategichurdles in its immediate future. But the new AbbVie will be s2020/5/13
-
Novavax scores $384M deal, CEPI's largest ever, to fund coronavirus vaccine workAfter winning a smallgrant for early vaccine work in March, Novavaxjustwon the largest-ever investment from CEPI, a globalcoalitionaidingCOVID-19 vaccine development. The grant of up to $384 million2020/5/12
-
Lilly cashes in on Loxo buyout with FDA approval for first-in-class cancer drug RetevmoIn two firsts, Eli Lilly has won its first approval for a pipeline drug coming out of the$8 billion acquisition of Loxo Oncology—and it's the first therapy specifically meant for cancer patients whos2020/5/12
-
Merck embarks on 3-year push to combine NJ sites into new HQMerck & Co. is preparing for a major real estate move in New Jersey. Theglobal drug giantaims to consolidate New Jersey campuses at a new headquarters in Rahway—its original HQ—by the end of 20232020/5/11
-
Is the PD-1 target behind Keytruda's small-cell miss? Merck exec says noBack in January, Merck said Keytruda—its anti-PD-1 therapy—had missed the mark in an area where two of its rivals hadsucceeded. Both those rivals are anti-PD-L1 treatments, so could that PD-1/PD-L1 d2020/5/11
-
Pfizer, Astellas show Xtandi helps early prostate cancer patients live longerPfizer and Astellas’ Xtandi is already approved to treat nonmetastatic castration-resistant prostate cancer, thanks to data showing it can stop tumors from spreading. But now it’s adding results that2020/5/9
-
Bristol Myers Squibb, awaiting Opdivo-Yervoy approval, trumpets 3-year lung cancer survival winJust days away from an FDA decision that could finally bring Bristol Myers Squibb’s Opdivo to previously untreated non-small cell lung cancer patients, the company’s Opdivo-Yervoy combo has put up po2020/5/8
-
J&J's Erleada extends lives by 14 months in nonmetastatic prostate cancerLast September, Johnson & Johnson said prostate cancer med Erleada had “barely missed” showing it could extend the lives of patients with nonmetastatic castration-resistant disease. But it’s now2020/5/7
-
AZ, Merck's Lynparza levels up in ovarian cancer, extending lives by 13 monthsWith competitor Zejula threatening to steal share after a key new approval, AstraZeneca and Merck’s Lynparza is taking things to the next level in BRCA-mutated ovarian cancer with evidence it can ext2020/5/7
-
Roche's Alecensa stays on top of Xalkori with long-term survival showingRoche made a splash at the American Society of Clinical Oncology (ASCO) annual meeting three years ago with data showing its Alecensa could top Pfizer’s Xalkori at keeping ALK-positive lung-cancerat2020/5/6